Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands

Clinical Therapeutics

Volumn 32, Issue 8, 2010, Pages 1479-1495

  Westra, Tjalke A ^a   de Vries, Robin ^a   Tamminga, Johannes J ^b   Sauboin, Christophe J ^c   Postma, Maarten J ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GLAXOSMITHKLINE   (Netherlands)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Booster; Cocooning; Cost effectiveness; Immunization; Maternal; Pertussis

Indexed keywords

PERTUSSIS VACCINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; IMMUNITY; INCIDENCE; MATERNAL VACCINATION; MEDICAL DECISION MAKING; MEDLINE; MORBIDITY; MORTALITY; NETHERLANDS; PERTUSSIS; PREVALENCE; QUALITY OF LIFE; SENSITIVITY ANALYSIS; THIRD TRIMESTER PREGNANCY; VACCINATION;

ADULT; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MASS VACCINATION; NETHERLANDS; PARENTS; PERTUSSIS VACCINE; PREGNANCY; QUALITY-ADJUSTED LIFE YEARS; WHOOPING COUGH;

EID: 77955904727     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.07.017     Document Type: Article

References (69)

1. Bjørnstad ON, Harvill ET Evolution and emergence of Bordetella in humans. Trends Microbiol. 2005, 13:355-359.
2. Anderson EL Prevention of pertussis. Semin Respir Infect. 1989, 4:284-292.
3. Rothstein E, Edwards K Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J. 2005, 24(Suppl 5):S44-S47.
4. de Melker HE, Versteegh FG, Schellekens JF, et al. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006, 53:106-113.
5. Wood N, Quinn HE, McIntyre P, Elliott E Pertussis in infants: Preventing deaths and hospitalisations in the very young. J Paediatr Child Health. 2008, 44:161-165.
6. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: Recommendations by the global pertussis initiative. Clin Infect Dis. 2004, 39:1802-1809. Global Pertussis Initiative.
7. Long SS, Welkon CJ, Clark JL Widespread silent transmission of pertussis in families: Antibody correlates of infection and symptomatology. J Infect Dis. 1990, 161:480-486.
8. de Greeff SC, Mooi FR, Westerhof A, et al. Pertussis disease burden in the household: How to protect young infants. Clin Infect Dis. 2010, 50:1339-1345.
9. Baptista PN, Magalhães V, Rodrigues LC, et al. Source of infection in household transmission of culture-confirmed pertussis in Brazil. Pediatr Infect Dis J. 2005, 24:1027-1028.
10. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: Who was the source?. Pediatr Infect Dis J. 2004, 23:985-989.
11. Halperin SA, Wang EE, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: Report of the Immunization Monitoring Program-Active (IMPACT). Clin Infect Dis. 1999, 28:1238-1243.
12. World Health Organization, Accessed April 2010. http://www.who.int.
13. Wilson TR Update on adolescent immunization: Review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis. J Pediatr Health Care. 2006, 20:229-237.
14. Loo IH, Mooi FR Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology. 2002, 148:2011-2018.
15. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in the Netherlands. Pediatr Infect Dis J. 2008, 27:218-223.
16. De Greeff SC, Dekkers AL, Teunis P, et al. Seasonal patterns in time series of pertussis. Epidemiol Infect. 2009, 137:1388-1395.
17. de Greeff SC, de Melker HE, Mooi FR Pertussis in the Netherlands [in Dutch]. Ned Tijdschr Geneeskd. 2010, 154:A1383.
18. Wendelboe AM, Van Rie A, Salmaso S, Englund JA Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005, 24(Suppl 5):S58-S61.
19. Raymond J, Armengaud JB, Cosnes-Lambe C, et al. Pertussis in young infants: Apnoea and intra-familial infection. Clin Microbiol Infect. 2007, 13:172-175.
20. Schellekens J, von König CH, Gardner P Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J. 2005, 24(Suppl 5):S19-S24.
21. Ward JI, Cherry JD, Chang SJ, et al. Bordetella pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT. Clin Infect Dis. 2006, 43:151-157. APERT Study Group.
22. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005, 353:1555-1563. APERT Study Group.
23. Wood N, McIntyre P, Marshall H, Roberton D Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J. 2010, 29:209-215.
24. Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008, 152:655-660. 660.e1.
25. Halasa NB, O'Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr. 2008, 153:327-332.
26. Mooi FR, de Greeff SC The case for maternal vaccination against pertussis. Lancet Infect Dis. 2007, 7:614-624.
27. Kowalzik F, Barbosa AP, Fernandes VR, et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J. 2007, 26:238-242.
28. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007, 26:293-299. Infant Pertussis Study Group.
29. Berbers GA, de Greeff SC, Mooi FR Improving pertussis vaccination. Hum Vaccin. 2009, 5:497-503.
30. Dutch guidelines for pharmacoeconomic research. Health Care Insurance Board 2006 Accessed April 2007. http://www.ispor.org/PEguidelines/countrydet.asp?c=22andt=1.
31. Bos JM, Postma MJ Using pharmacoeconomics for policy making: Is rational decision making enhanced by applying thresholds for cost-effectiveness?. Expert Rev Pharmacoecon Outcomes Res. 2004, 4:247-250.
32. McIntyre P, Wood N Pertussis in early infancy: Disease burden and preventive strategies. Curr Opin Infect Dis. 2009, 22:215-223.
33. Gustafsson L, Hessel L, Storsaeter J, Olin P Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006, 118:978-984.
34. Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics. 2005, 116:e285-e294. Centers for Disease Control and Prevention.
35. De Greeff SC, Mooi F, Westerhof A, De Melker H Sources of infection of pertussis in infants too young to be vaccinated. Poster presented at the European Society of Clinical Microbiology and Infectious Diseases April 19-22, 2008, Abstract P1340.
36. Lichty JA, Slavin B, Bradford WL An attempt to increase resistance to pertussis in newborn infants by immunizing their mothers during pregnancy. J Clin Invest. 1938, 17:613-621.
37. Van Rie A, Wendelboe AM, Englund JA Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J. 2005, 24(Suppl 5):S62-S65.
38. Shakib JH, Ralston S, Raissy HH, et al. Pertussis antibodies in postpartum women and their newborns. J Perinatol. 2010, 30:93-97.
39. Francis PT Maternal vaccination against pertussis. Lancet Infect Dis. 2008, 8:214. author reply.
40. Francis PT Maternal vaccination against pertussis. Lancet Infect Dis. 2008, 8:214-215.
41. Nooitgedagt JE, de Greeff SC, Elvers BH, et al. Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin. Clin Infect Dis. 2009, 49:1086-1089.
42. de Voer RM, van der Klis FR, Nooitgedagt JE, et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis. 2009, 49:58-64.
43. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis. 2004, 190:335-340.
44. Saffar MJ, Ajami A, Khalilian AR, et al. Pertussis seroimmunity among mother-infant pairs and infant immune response to pertussis vaccination. Indian Pediatr. 2007, 44:916-918.
45. Blatter M, Friedland LR, Weston WM, et al. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009, 27:765-772.
46. European Medicines Agency, Accessed April 2010. http://www.ema.europa.eu.
47. CBS Statline Centraal Bureau voor de Statistiek, Accessed December 2009. http://statline.cbs.nl.
48. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: Pertussis in UK infants [published correction appears in Arch Dis Child. 2006;91:453]. Arch Dis Child. 2003, 88:802-806.
49. Greenberg D, Bamberger E, Ben-Shimol S, et al. Pertussis is under diagnosed in infants hospitalized with lower respiratory tract infection in the pediatric intensive care unit. Med Sci Monit. 2007, 13:CR475-CR480.
50. Crowcroft NS, Andrews N, Rooney C, et al. Deaths from pertussis are underestimated in England. Arch Dis Child. 2002, 86:336-338.
51. Shaikh R, Guris D, Strebel PM, Wharton M Underreporting of pertussis deaths in the United States: Need for improved surveillance. Pediatrics. 1998, 101:323.
52. de Vries R, Postma MJ Individually-based dynamic modeling of infectious diseases: Cost-effectiveness of adolescent pertussis booster vaccination for the Netherlands. Value Health. 2009, 12:A232-A.
53. Prismant, Accessed April 2007. http://www.prismant.nl.
54. Pediatric Intensive Care Unit, Accessed April 2007. http://www.picu.nl.
55. Lee GM, Murphy TV, Lett S, et al. Cost effectiveness of pertussis vaccination in adults. Am J Prevent Med. 2007, 32:186-193.
56. Lee GM, Salomon JA, LeBaron CW, Lieu TA Health-state valuations for pertussis: Methods for valuing short-term health states. Health Qual Life Outcomes. 2005, 3:17.
57. Oostenbrink J, Bouwmans C, Koopmanschap M, Rutten F Guideline for costing research, methods and standardized prices for economic evaluations in health care. Diemen: Health Care Insurance Board 2004.
58. Hay JW, Ward JI Economic considerations for pertussis booster vaccination in adolescents. Pediatr Infect Dis J. 2005, 24(Suppl 6):S127-S133.
59. de Greeff SC, Lugnér AK, van den Heuvel DM, et al. Economic analysis of pertussis illness in the Dutch population: Implications for current and future vaccination strategies. Vaccine. 2009, 27:1932-1937.
60. Laboratory for Infectious Diseases, Accessed April 2007. http://www.infectielab.nl.
61. Tormans G, Van Doorslaer E, van Damme P, et al. Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. Eur J Pediatr. 1998, 157:395-401.
62. Thomas PF, McIntyre PB, Jalaludin BB Survey of pertussis morbidity in adults in western Sydney. Med J Aust. 2000, 173:74-76.
63. Riffelmann M, Littmann M, Hülsse C, et al. Pertussis: Incidence, symptoms and costs [in German]. Dtsch Med Wochenschr. 2006, 131:2829-2934.
64. Welte R, van den Dobbelsteen G, Bos JM, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making. Vaccine. 2004, 23:470-479.
65. Health Care Insurance Board Energy Users Association of Australia, Accessed January 2008. http://www.cvz.nl.
66. Coupé VM, van Ginkel J, de Melker HE, et al. HPV16/18 vaccination to prevent cervical cancer in the Netherlands: Model-based cost-effectiveness. Int J Cancer. 2009, 124:970-978.
67. Scuffham PA, McIntyre PB Pertussis vaccination strategies for neonates-an exploratory cost-effectiveness analysis. Vaccine. 2004, 22:2953-2964.
68. Lee GM, Riffelmann M, Wirsing von Konig CH Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine. 2008, 26:3673-3679.
69. ClinicalTrials.gov Energy Users Association of Australia, Accessed December 2009. http://www.clinicaltrials.gov.